Dr. Kukreja on key kidney cancer research presented at SUO 2023

EP: 1.SUO 2023: Dr. Cookson discusses prostate cancer highlights

Now Viewing

EP: 2.Dr. Kukreja on key kidney cancer research presented at SUO 2023

EP: 3.Dr. Schmidt recaps key bladder cancer research from SUO 2023

In this video, Janet Kukreja, MD, outlines key kidney cancer research that was presented at this year’s Society of Urologic Oncology Annual Meeting, held in Washington DC. Kukreja is a urologic oncologist and an associate professor of surgery-urology at the University of Colorado in Aurora, CO. During the discussion, Kukreja touch on the following abstracts:

• Poster 6: SWOG S1931 (PROBE): Phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer [NCT04510597] – Hyung Kim, MD
• Poster 7: Safety of partial and radical nephrectomy for complex locally advanced renal cell carcinoma after neo-adjuvant immune checkpoint inhibition (durvalumab +/- tremelimumab) – Joseph Zabell, MD
• Poster 101: Socioeconomic and demographic disparities in immunotherapy for advanced clear cell renal cell carcinoma – Levi Holland, MD
• Poster 13: Limited utility of quantitative thresholds on 99MTC-sestamibi SPECT/CT for distinguishing renal cell carcinoma from oncocytic renal masses – Robert S. Wang, MD
• Poster 103: Comprehensive Immunogenomic Evaluation of Patients Undergoing Consolidative Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Patients Treated with Immune Checkpoint Blockade – Stephen Reese, MD